Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Guardant Health Inc
(NQ:
GH
)
26.41
-2.61 (-8.98%)
Streaming Delayed Price
Updated: 3:51 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Guardant Health Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
April 25, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
April 21, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
April 19, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
April 18, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Earnings Perspective: Return On Capital Employed
March 16, 2023
Via
Benzinga
Looking Into Guardant Health's Return On Capital Employed
February 28, 2023
Via
Benzinga
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
April 11, 2023
From
Guardant Health, Inc.
Via
Business Wire
FTC Orders Biotech Illumina To Unwind Grail Deal Amid Icahn Battle
April 03, 2023
The FTC ordered Monday that biotech firm Illumina must unwind its $8 billion purchase of the cancer-testing startup Grail. ILMN stock fell.
Via
Investor's Business Daily
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
March 21, 2023
From
Guardant Health, Inc.
Via
Business Wire
Analyst Expectations for Guardant Health's Future
February 27, 2023
Via
Benzinga
Earnings Outlook For Guardant Health
February 22, 2023
Via
Benzinga
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
March 10, 2023
From
Guardant Health, Inc.
Via
Business Wire
2 Stocks That Could Rebound and Rise 30% or More in 2023
March 10, 2023
They're down, but they aren't yet out.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
March 09, 2023
Via
Benzinga
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market
March 06, 2023
Investing now is an admittedly risky bet, but the payoff could be massive.
Via
The Motley Fool
Musa Tariq Joins Guardant Health Board of Directors
February 27, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
February 23, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Participate in Upcoming March Investor Conferences
February 17, 2023
From
Guardant Health, Inc.
Via
Business Wire
25 AI Stocks to Buy Right Now
February 16, 2023
Looking to benefit from the AI boom started by ChatGPT? Here are the best AI stocks to buy for the emerging market frenzy.
Via
InvestorPlace
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
February 15, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
February 08, 2023
From
Guardant Health, Inc.
Via
Business Wire
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development
February 04, 2023
Structure Therapeutics raised $161 million in a successful US IPO to support development of its oral therapeutics portfolio aimed at chronic metabolic and pulmonary diseases. Schrödinger is a...
Via
Talk Markets
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
February 02, 2023
From
Guardant Health Inc.
Via
Business Wire
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
February 02, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
February 01, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
January 31, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
January 30, 2023
From
Guardant Health, Inc.
Via
Business Wire
Down 40% in 2022, Can Exact Sciences Recover in 2023?
January 23, 2023
Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous.
Via
The Motley Fool
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
January 19, 2023
From
Guardant Health, Inc.
Via
Business Wire
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
January 17, 2023
From
Guardant Health, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.